igeahub.com
Boehringer Ingelheim Gives Global Development and Commercial Rights to Amgen for Investigational BiTE® Immuno-Oncology Drug for Multiple Myeloma - IgeaHub
Sept. 1, 2016 Boehringer Ingelheim and Amgen have announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for